NCT03890614View on ClinicalTrials.gov

Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity

RecruitingOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Hematologic Malignancy
Interventions
OTHER

Ancillary-Correlative - Creation of three-dimensional myeloma organoids using marrow aspirates

Bone marrow aspirates will be collected from participants with hematologic malignancy being evaluated for relapsed disease to create three-dimensional constructs using a three-dimensional bioprinting methodology for automated organoid biofabrication.

Trial Locations (1)

27157

RECRUITING

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER